


# PRODUCT INFORMATION



## Bezafibrate

Item No. 10009145

**CAS Registry No.:** 41859-67-0  
**Formal Name:** 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid  
**Synonyms:** Benzofibrate, BM 15075  
**MF:** C<sub>19</sub>H<sub>20</sub>ClNO<sub>4</sub>  
**FW:** 361.8  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 229 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Bezafibrate is supplied as a crystalline solid. A stock solution may be made by dissolving the bezafibrate in the solvent of choice, which should be purged with an inert gas. Bezafibrate is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of bezafibrate in ethanol is approximately 3 mg/ml and approximately 30 mg/ml in DMSO and DMF.

Bezafibrate is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, bezafibrate should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Bezafibrate has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Bezafibrate is a non-selective agonist of peroxisome proliferator-activated receptors (PPARs; EC<sub>50</sub>s = 50, 60, and 20 μM for human PPARα, PPARγ, and PPARδ, respectively).<sup>1</sup> It reduces triglyceride levels and the size of lipid droplets in an oleic acid-induced HepaRG hepatocyte model of steatosis when used at a concentration of 25 μM.<sup>2</sup> Bezafibrate (10 mg/kg per day) reduces plasma VLDL and LDL mass and triglyceride and free fatty acid levels in a high-fructose plus lard diet-induced rat model of insulin resistance.<sup>3</sup>

### References

- Willson, T.M., Brown, P.J., Sternbach, D.D., *et al.* The PPARs: From orphan receptors to drug discovery. *J. Med. Chem.* **43**(4), 528-550 (2000).
- Rogue, A., Anthérieu, S., Vluggens, A., *et al.* PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells. *Toxicol. Appl. Pharmacol.* **276**(1), 73-81 (2014).
- Matsui, H., Okumura, K., Kawakami, K., *et al.* Improved insulin sensitivity by bezafibrate in rats: Relationship to fatty acid composition of skeletal-muscle triglycerides. *Diabetes* **46**(3), 348-353 (1997).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/10/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM